At the time of writing, Sage Therapeutics Inc [SAGE] stock is trading at $7.35, down -1.21%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The SAGE shares have gain 5.91% over the last week, with a monthly amount glided 34.12%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Sage Therapeutics Inc [NASDAQ: SAGE] stock has seen the most recent analyst activity on November 21, 2024, when RBC Capital Mkts upgraded its rating to a Sector Perform but kept the price target unchanged to $4 for it. On October 04, 2024, downgrade downgraded it’s rating to Sector Perform and revised its price target to $4 on the stock. TD Cowen downgraded its rating to a Hold and decreased its price target to $10 on July 30, 2024. JP Morgan downgraded its rating to a Neutral and reduced its price target to $12 on July 25, 2024. Robert W. Baird started tracking with a Neutral rating for this stock on May 29, 2024, and assigned it a price target of $15. In a note dated May 29, 2024, Citigroup initiated an Sell rating and provided a target price of $8 on this stock.
For the past year, the stock price of Sage Therapeutics Inc fluctuated between $4.62 and $27.39. Currently, Wall Street analysts expect the stock to reach $13 within the next 12 months. Sage Therapeutics Inc [NASDAQ: SAGE] shares were valued at $7.35 at the most recent close of the market. An investor can expect a potential return of 76.87% based on the average SAGE price forecast.
Analyzing the SAGE fundamentals
According to Sage Therapeutics Inc [NASDAQ:SAGE], the company’s sales were 106.40M for trailing twelve months, which represents an 337.08% jump. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -3.49%, Pretax Profit Margin comes in at -3.17%, and Net Profit Margin reading is -3.17%. To continue investigating profitability, this company’s Return on Assets is posted at -0.54, Equity is -0.5 and Total Capital is -0.66. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.26 points at the first support level, and at 7.18 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.48, and for the 2nd resistance point, it is at 7.62.
Ratios To Look Out For
It is important to note that Sage Therapeutics Inc [NASDAQ:SAGE] has a current ratio of 10.02. Further, the Quick Ratio stands at 10.02, while the Cash Ratio is 1.65. Considering the valuation of this stock, the price to sales ratio is 4.23, the price to book ratio is 0.81.
Transactions by insiders
Recent insider trading involved JONAS JEFFREY M, Officer, that happened on Dec 10 ’24 when 7500.0 shares were purchased.
